Latest Breaking News On - Fu sheng wang - Page 1 : comparemela.com

/PRNewswire/ Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the first subject has been dosed in the China Phase II clinical trial of.

Hong kongFu sheng wangJinzij wuLinghua liGuangzhou medical universityHong kong stock exchangeAcademician of the chinese academy sciencesAscletis pharma incPrnewswire ascletis pharma incChina phaseChinese academyInfectious diseasesFifth medical centreGuangzhou eighth peopleGuangzhou medicalAscletis pharma inc